

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Medibio Limited
<b>ABN</b>	58 008 130 336

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Claude Solitario
<b>Date of last notice</b>	4 September 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Claude Solitario <Solitario Family A/C> (Director)
<b>Date of change</b>	20 December 2019
<b>No. of securities held prior to change</b>	<b>Direct</b> 3,000 Fully Paid Ordinary shares  <b>Indirect</b> 41,809,576 Fully Paid Ordinary Shares; 30,333,040 Quoted Options exercisable at \$0.03 each and expiring 1 December 2021; 3,000,000 Unlisted Options exercisable at \$0.014 expiring 13 June 2023; and 4,000,000 Unlisted Options exercisable at \$0.015 per option expiring 19 August 2024.
<b>Class</b>	Unlisted Options exercisable at \$0.011 (1.1 cents) per option expiring on 20 December 2023
<b>Number acquired</b>	3,000,000

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	<p><b>Direct</b> 3,000 Fully Paid Ordinary shares; 3,000,000 Unlisted Options exercisable at \$0.011 per option expiring 20 December 2023.</p> <p><b>Indirect</b> 41,809,576 Fully Paid Ordinary Shares; 30,333,040 Quoted Options exercisable at \$0.03 each and expiring 1 December 2021; 3,000,000 Unlisted Options exercisable at \$0.014 expiring 13 June 2023; and 4,000,000 Unlisted Options exercisable at \$0.015 per option expiring 19 August 2024.</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Unlisted options issued as approved by shareholders on 22 November 2019 at the Company's Annual General Meeting.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entity	Medibio Limited
ABN	58 008 130 336

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter Carlisle
Date of last notice	18 June 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	20 December 2019
No. of securities held prior to change	125,500 Ordinary Fully Paid Shares; 559,556 Unlisted Options exercisable at \$0.44, expiring 18 June 2022; 4,000,000 Unlisted Options exercisable at \$0.014 expiring 13 June 2023.
Class	Unlisted Options exercisable at \$0.011 (1.1 cents) per option expiring on 20 December 2023
Number acquired	3,600,000
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	125,500 Ordinary Fully Paid Shares; 559,556 Unlisted Options exercisable at \$0.44, expiring 18 June 2022; 4,000,000 Unlisted Options exercisable at \$0.014 expiring 13 June 2023; 3,600,000 Unlisted Options exercisable at \$0.011 (1.1 cents) per option expiring on 20 December 2023.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Unlisted options issued as approved by shareholders on 22 November 2019 at the Company's Annual General Meeting.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

### Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Medibio Limited
<b>ABN</b>	58 008 130 336

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Melanie Leydin
<b>Date of last notice</b>	4 September 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	TMENA Pty Ltd <Combivan Pty Ltd Account> (Director)
<b>Date of change</b>	20 December 2019
<b>No. of securities held prior to change</b>	2,600,000 Unlisted options exercisable at \$0.02 expiring on 19 August 2023
<b>Class</b>	Unlisted Options exercisable at \$0.011 (1.1 cents) per option expiring on 20 December 2023
<b>Number acquired</b>	2,200,000
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil

---

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

---

No. of securities held after change	2,600,000 Unlisted options exercisable at \$0.02 expiring on 19 August 2023; 2,200,000 Unlisted Options exercisable at \$0.011 (1.1 cents) per option expiring on 20 December 2023.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Unlisted options issued as approved by shareholders on 22 November 2019 at the Company's Annual General Meeting.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

### Part 3 – <sup>+</sup>Closed period

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

---

<sup>+</sup> See chapter 19 for defined terms.